Farmaco sviluppa seno 
In Tanzania alcuni uomini in terapia anti-retrovirale (ARV) per prolungare la vita contro l'Aids soffrono di effetti collaterali tra i quali l'imbarazzante sviluppo del seno. Alcuni farmaci non andrebbero presi in combinazione e a complicare le cose dovrebbero essere presi con una dieta bilanciata, impossibile con la carestia


Man on ARV develops abnormal breasts. Some Tanzania men on anti-retroviral (ARV) drugs have experienced abnormal breast enlargement similar to that of women. There are even cases where women taking the life prolonging drug against HIV complaining of queer side effects including becoming disabled. Joseph Mkanda, 43, one of the victims, said he developed strange symptoms plus growing breasts after taking the drugs. Initially, he suspected the cause to be lack of a balanced diet, but he soon realised that the main problem was the type of drugs he was taking. “I feel very much ashamed to go out of my house, because I have developed breasts like a woman. I fear that other people would laugh at me,” he said from his Mtwara-base. “I went to one of the medical doctors in my village, who told me that such signs were normal for people suffering from AIDS who have been taking the drugs for a long time. At the moment, I don’t know what to do or where to go,” said Mkanda [...] There is no alternative to taking ARVs by HIV positive persons, even though it is challenging to adhere to the treatment because of lack of resources to get proper diet. According to health community reports certain drugs should not be used together because of the way they interact. For example, Idovudine and Stavudine should not be used together, and Zalcitabine should not be combined with Didanosine, Stavudine, or Lamivudine [...] Meanwhile United States of America confirmed that it has phased out the Stavudine ARV drug because of its side effects. Despite its users developing a number of disorders, including some men using it growing breasts, Stavudine ARV is one of the drugs still being used in the country... Africa News

Nessun commento: